EVOK
Evoke Pharma, Inc.11.00
+0.04+0.37%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
18.95MP/E (TTM)
-Basic EPS (TTM)
-1.38Dividend Yield
0%Recent Filings
8-K
Evoke acquired for $11/share
Evoke Pharma completed its merger with QOL Medical's subsidiary on December 17, 2025, after a tender offer closed December 15 with 67.63% of shares tendered at $11.00 cash per share. The company delists from Nasdaq today; trading halts. Evoke now a private wholly owned subsidiary. Leadership cleared out.
8-K
Evoke set for $11/share acquisition
Evoke Pharma entered a merger agreement on November 4, 2025, with QOL Medical to be acquired for $11.00 per share in cash, expected to close Q4 2025 pending shareholder tender and conditions. Q3 net product sales hit $4.3M, up 61% year-over-year, while net loss narrowed to $1.2M from $1.3M. Gimoti patent extends to 2038. Deal risks include closing uncertainties.
10-Q
Q3 FY2025 results
Evoke Pharma ramped net product sales to $4.3M in Q3 ended September 30, 2025, up 61% y/y from $2.7M and ~11% q/q (derived) from Q2, driven by expanded pharmacy networks and higher refill rates via Eversana. SG&A swelled 39% y/y to $5.3M on profit sharing, yet operating loss narrowed to $1.1M from $1.3M y/y. Cash dipped to $11.6M after $2.1M nine-month operating burn, with $5M note payable (10%, due on demand) and $2.5M accrued interest current due to Eversana NPQTR risk. Sales grow fast. QOL Medical merger announced November 3 for $11/share, expected Q4 close; yet deal failure risks Nasdaq compliance.
8-K
Evoke set for $11/share buyout
Evoke Pharma signed a merger agreement on November 3, 2025, with QOL Medical, which will launch a tender offer for all shares at $11.00 cash per share—a 139.7% premium to the prior close. The board unanimously approved, backed by support agreements covering 10.4% of shares; post-tender merger delists Evoke as QOL subsidiary, with options accelerating fully and warrants cash-settled if in-the-money. Deal targets Q4 2025 close, yet faces minimum tender, regulatory, and no-shop risks.
10-Q
Q2 FY2025 results
Evoke Pharma's Q2 net product sales climbed 47% y/y to $3.8M, fueled by expanded pharmacy networks and higher refill rates, while YTD sales rose 59% to $6.8M versus prior year. Gross margins held steady despite a 304% y/y jump in cost of goods sold to $0.2M, tied to stability testing timing, but operating losses widened 27% y/y to $1.6M amid surging SG&A from Eversana profit sharing. Diluted EPS improved to $(0.62) from $(0.93), reconciling with 2.55M weighted shares; net loss tracked operating loss closely, with minimal other expense drag from interest. Cash dipped to $12.1M after $1.6M operating burn, offset by minor ESPP inflows, while the $5.0M Eversana note at 10%—now current due to termination risk—looms large alongside $7.4M total debt. No non-GAAP metrics disclosed in the 10-Q. Yet regulatory pressures from the Inflation Reduction Act threaten pricing power.
IPO
Website
Employees
Sector
Industry
EBS
Emergent BioSolutions Inc.
12.19-0.14
ELTP
Elite Pharmaceuticals, Inc.
0.50+0.00
EOLS
Evolus, Inc. Common Stock
7.22+0.08
EVFM
Evofem Biosciences, Inc.
0.01-0.00
EVO
Evotec SE
3.01+0.03
NSRX
Nasus Pharma Ltd.
6.80+0.00
SBFM
Sunshine Biopharma Inc.
1.38-0.01
TAK
Takeda Pharmaceutical Company L
14.53-0.08
TEVA
Teva Pharmaceutical Industries
30.10-0.03
XERS
Xeris Biopharma Holdings, Inc.
7.10+0.05